SIX · TECN.SW
Tecan Group AG
CHF 255.20+CHF 8.40 (+3.4%)
Tecan Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
Loading market information…
SIX · COPN.SW · CHF
Stock price, dividends, earnings
Quote as of Aug 14, 2026, 03:31 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CHF. Historical prices are not a forecast.
Cosmo Pharmaceuticals N.V.’s quoted price sits in the lower half of its reported 52-week range, 54.64% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Cosmo Pharmaceuticals N.V.’s forward annual dividend is CHF 1.95 per share, paid annual. The forward yield is 3.33% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Cosmo Pharmaceuticals N.V.’s next earnings report is currently expected on Mar 24, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cosmo Pharmaceuticals N.V.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Latest available per-share figures in CHF. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2023 | Jul 26, 2023 | CHF 0.09 | CHF 42.69M |
|---|
| Q4 2022 | Mar 23, 2023 | CHF 0.57 | CHF 60.35M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 255.20+CHF 8.40 (+3.4%)
Tecan Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.62% below the high.
CHF 76.30+CHF 0.10 (+0.13%)
SKAN Group AG’s quoted price sits in the upper half of its reported 52-week range, 1.42% below the high.
CHF 43.40-CHF 0.30 (-0.69%)
PolyPeptide Group AG’s quoted price sits in the upper half of its reported 52-week range, 13.37% below the high.
CHF 4.58-CHF 0.01 (-0.22%)
Idorsia Ltd’s quoted price sits in the lower half of its reported 52-week range, 39.39% below the high.
CHF 97.30+CHF 2.00 (+2.1%)
Medartis Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.92% below the high.
CHF 14.20-CHF 0.15 (-1.05%)
Aevis Victoria S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
CHF 71.50-CHF 1.90 (-2.59%)
Basilea Pharmaceutica AG’s quoted price sits in the upper half of its reported 52-week range, 5.67% below the high.
CHF 20.84-CHF 0.10 (-0.48%)
Kuros Biosciences AG’s quoted price sits in the lower half of its reported 52-week range, 35.84% below the high.
